Adrian Ion Bot - 16 Dec 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: Director
Issuer ticker: RNAC
Reported as of: 16 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Dec 2025, 17:05:19 UTC
Source filing: View source filing
Reporting owner signature: /s/ Matthew Bartholomae, Attorney-in-fact for Adrian Ion Bot

Key filing fact

Adrian Ion Bot filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 18 Dec 2025.

Key facts

This page summarizes Adrian Ion Bot's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Dec 2025, 17:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002101801 Primary reporting owner

Bot Adrian Ion

Relationship: Director
Address: C/O CARTESIAN THERAPEUTICS, INC., 7495 NEW HORIZON WAY, FREDRICK
Signature: /s/ Matthew Bartholomae, Attorney-in-fact for Adrian Ion Bot
Signature date: 18 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNAC transaction

Common Stock

Award

Transaction value: $0
Shares: +5,800
Change %
Price: $0.000000
Shares after: 5,800
Date: 16 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAC transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,200
Change %
Price: $0.000000
Shares after: 17,200
Date: 16 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,200
Exercise price: $8.29
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028.

Footnote F2

This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028.